<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40892621</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of a Novel Triple Single-Pill For Uncontrolled Hypertension: the OPTION TREAT Trial.</ArticleTitle><Pagination><StartPage>102175</StartPage><MedlinePgn>102175</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.102175</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00600-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Novel single-pill combinations with blood pressure (BP)-lowering agents are needed to increase treatment options for hypertension.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the efficacy and safety of a novel single-pill (candesartan cilexetil, amlodipine, and chlorthalidone) compared with an active control (valsartan, amlodipine, and hydrochlorothiazide) for uncontrolled hypertension.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">OPTION TREAT was a randomized, double-blind, double-dummy, noninferiority trial conducted across 19 sites in Brazil. Participants with an office systolic BP of 140-180 mmHg and a diastolic BP of 90-110 mmHg despite dual therapy were randomized in a 1:1 ratio to receive either the experimental treatment or the active control for 12 weeks. The primary outcome was the mean change in office systolic BP from baseline to week 12. Prespecified noninferiority margin was 3 mmHg. Secondary outcomes included mean changes in diastolic BP and adverse events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 703 participants were included (mean age 57.8 years, 62.7% women, baseline office BP of 153.0/95.6 mmHg). At 12 weeks, the least square mean change in systolic BP was -22.6 mmHg in the experimental group versus -18.2 mmHg in the control group (between-group difference -4.4 mmHg; 90% CI -6.3 to -2.5; p &lt; 0.001). Diastolic was also reduced in both groups, with greater reductions in the experimental group (-13.8 mmHg vs. -12.0 mmHg; p = 0.008). Adherence was high and serious adverse events were rare.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients with uncontrolled hypertension, a novel triple single-pill containing candesartan cilexetil, amlodipine, and chlorthalidone improved BP control at 12 weeks and had a reasonable safety profile. (Efficacy and Safety of a Novel Triple Single-Pill Combination Therapy Compared with an Active Control in Patients with Uncontrolled Hypertension [OPTION TREAT]: NCT05920005).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madrini</LastName><ForeName>Vagner</ForeName><Initials>V</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavares</LastName><ForeName>Caio A M</ForeName><Initials>CAM</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, Brazil; Instituto do Cora&#xe7;&#xe3;o (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albuquerque</LastName><ForeName>Monica T A</ForeName><Initials>MTA</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvestre</LastName><ForeName>Odilson M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Universidade Federal do Acre, Rio Branco, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felicio</LastName><ForeName>Jo&#xe3;o S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Jo&#xe3;o de Barros Barreto University Hospital, Federal University of Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>Fabio S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Centro de Pesquisa Cl&#xed;nica do Cora&#xe7;&#xe3;o, Aracaju, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hissa</LastName><ForeName>Miguel N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Centro de Pesquisas em Diabetes e Doen&#xe7;as End&#xf3;crino-Metab&#xf3;licas/Cl&#xed;nica Popular Endocrinologia, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antunes</LastName><ForeName>Murillo O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Hospital Universit&#xe1;rio S&#xe3;o Francisco de Assis na Provid&#xea;ncia de Deus da Universidade de S&#xe3;o Francisco, Bragan&#xe7;a Paulista, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mota-Gomes</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Centro Universit&#xe1;rio CESMAC, Macei&#xf3;, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidotti</LastName><ForeName>Maria H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Centro I9 Pesquisa Cl&#xed;nica, Campinas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Fl&#xe1;vio D</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>Hospital de Cl&#xed;nicas de Porto Alegre, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcondes-Braga</LastName><ForeName>Fabiana G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Centro CIPES, S&#xe3;o Jos&#xe9; dos Campos, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filho</LastName><ForeName>Conrado R H</ForeName><Initials>CRH</Initials><AffiliationInfo><Affiliation>W&amp;H Cardiologia, Joinville, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troiani do Nascimento</LastName><ForeName>Charlene</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Regional de Presidente Prudente, Presidente Prudente, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastos</LastName><ForeName>Rafael A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Centro Ruy Azeredo, Goi&#xe2;nia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand&#xe3;o</LastName><ForeName>Andrea A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Faculdade de Ci&#xea;ncias M&#xe9;dicas-Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cest&#xe1;rio</LastName><ForeName>Elisabeth E S</ForeName><Initials>EES</Initials><AffiliationInfo><Affiliation>Cl&#xed;nica Cardiol&#xf3;gica, Votuporanga, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bortolotto</LastName><ForeName>Luiz A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castilho</LastName><ForeName>Vivienne C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Libbs Pharmaceuticals, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapa</LastName><ForeName>Maura G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Libbs Pharmaceuticals, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magaton</LastName><ForeName>Erida A P</ForeName><Initials>EAP</Initials><AffiliationInfo><Affiliation>Libbs Pharmaceuticals, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Paula B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Libbs Pharmaceuticals, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albuquerque</LastName><ForeName>Camila S N</ForeName><Initials>CSN</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Lucas R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berwanger</LastName><ForeName>Ot&#xe1;vio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>George Institute for Global Health UK, London, United Kingdom; Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guimar&#xe3;es</LastName><ForeName>Patricia O</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, Brazil. Electronic address: patricia.oguimaraes@einstein.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05920005</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">blood pressure control</Keyword><Keyword MajorTopicYN="N">fixed-dose combination</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">single-pill combination</Keyword><Keyword MajorTopicYN="N">triple therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>22</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>22</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>12</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40892621</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.102175</ArticleId><ArticleId IdType="pii">S2772-963X(25)00600-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>